Finally! On-Demand Treatment
for Acute Abdominal or Facial Attacks of HAE* in Adults and Adolescents

On-demand means treating patients with Berinert® when an acute abdominal or facial attack occurs. For example, if a patient has 7 abdominal or facial attacks in a year, you treat the patient 7 times.

*Hereditary angioedema.

Important Safety Information

Berinert®, C1 Esterase Inhibitor (Human) is a plasma-derived concentrate of C1 Esterase Inhibitor (Human), indicated for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) in adult and adolescent patients. The safety and efficacy of Berinert® for prophylactic therapy have not been established.

Berinert® is contraindicated in individuals who have experienced an anaphylactic or severe systemic reaction to C1 esterase inhibitor preparations.

Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis). If hypersensitivity is suspected, immediately discontinue administration and initiate appropriate treatment. Epinephrine should be immediately available for treatment of acute severe hypersensitivity reactions.

Thrombotic events have occurred in patients receiving off-label high doses of Berinert®. Monitor patients with known risk factors for thrombotic events.

Berinert® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most serious adverse reaction reported in subjects in clinical studies who received Berinert® is an increase in the severity of pain associated with HAE. The most common adverse reactions observed in more than 4% of subjects after Berinert® treatment were headache, abdominal pain, nausea, muscle spasms, pain, diarrhea, and vomiting.

Berinert® has not been evaluated in pregnant women or nursing mothers; benefits of treatment should be weighed against potential risks in pregnant women, and Berinert® should be given to nursing mothers only if clearly needed.

The safety and efficacy of Berinert® have not been established in children (ages 0 through 12) or in the geriatric population.

Please see Brief Summary of Prescribing Information on following pages.
Get Started and Prescribe Berinert® Today

Berinert® Expert Network (B.E.N.™) makes it easy for you and your patients, and helps you:

• Get access to Berinert®
• Navigate insurance issues and questions
• Offer valuable CSL Behring Assurance and Assistance Programs to your patients who need them

Berinert®, C1 Esterase Inhibitor (Human) is for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) in adult and adolescent patients. The safety and efficacy of Berinert® for prophylactic therapy have not been established.

Please see Brief Summary of Prescribing Information on following pages.
**CSL Behring**

**BRIEF SUMMARY OF PRESCRIBING INFORMATION**

**Berinert® [C1 Esterase Inhibitor (Human)]**

Freeze-dried powder

Before prescribing, please consult full prescribing information, a brief summary of which follows. Some text and references refer to full prescribing information.

1 **INDICATIONS AND USAGE**

Berinert is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) in adult and adolescent patients.

The safety and efficacy of Berinert for prophylactic therapy have not been established.

4 **CONTRAINDICATIONS**

Berinert is contraindicated in individuals who have experienced life-threatening hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor preparations.

**5 WARNINGS AND PRECAUTIONS**

5.1 Hypersensitivity

Severe hypersensitivity reactions may occur. Epinephrine should be immediately available for treatment of acute severe hypersensitivity reaction (see Patient Counseling Information (17)).

5.2 Thrombotic Events

Thrombotic events have been reported in association with Berinert when used off-label and at higher than labeled doses. Animal studies have confirmed the risk of thrombosis from intravenous administration of C1 esterase inhibitor products (see Overdosage (10) and Animal Toxicology and Pharmacology (13.2)).

5.3 Transmission of Infectious Agents

Because Berinert is made from human blood, it may contain infectious agents (eg, viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent) that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by processes demonstrated to inactivate and/or remove certain viruses during manufacturing (see Description (11) and Patient Counseling Information (17)).

Despite these measures, such products may still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products.

Since 1979, a few suspected cases of viral transmission have been reported with the use of Berinert outside the US, including cases of acute hepatitis C. From the incomplete information available from these cases, it was not possible to determine with certainty if the infections were or were not related to prior administration of Berinert.

The physician should discuss the risks and benefits of this product with the patient before prescribing or administering it to the patient. (See Patient Counseling Information (17.1)).

All infections thought by a physician possibly to have been transmitted by Berinert should be reported by lot number, by the physician, or other healthcare provider to the CSL Behring Pharmacovigilance Department at 1-866-915-6958.

6 **ADVERSE REACTIONS**

The most serious adverse reaction reported in subjects enrolled in clinical studies who received Berinert was an increase in the severity of pain associated with HAE.

The most common adverse reactions that have been reported in greater than 4% of the subjects who received Berinert in clinical studies were abdominal pain, bloating, cramps, nausea, vomiting, and diarrhea.

6.1 Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Placebo-controlled Clinical Study

In the placebo-controlled clinical study, referred to as the randomized clinical trial (RCT) (see Clinical Studies (14)), 124 subjects experiencing an acute moderate to severe abdominal or facial HAE attack were treated with Berinert (either a 10 unit per kg body weight or a 20 unit per kg body weight dose), or placebo (physiological saline solution).

The treatment-emergent serious adverse reactions/events that occurred in 5 subjects in the RCT were laryngeal edema, facial attack with laryngeal edema, swelling (shoulder and chest), exacerbation of hereditary angioedema, and laryngospasm.

**Table 1: Adverse Reactions Occurring up to 4 Hours After Initial Infusion in More Than 4% of Subjects, Irrespective of Causality**

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>Number (%) of Subjects Reporting Adverse Reactions</th>
<th>Number (%) of Subjects Reporting Adverse Reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea*</td>
<td>3 (7%)</td>
<td>5 (11.9%)</td>
</tr>
<tr>
<td>Diarrhea†</td>
<td>4 (9.5%)</td>
<td>9 (20.9%)</td>
</tr>
<tr>
<td>Headache†</td>
<td>4 (9.5%)</td>
<td>9 (20.9%)</td>
</tr>
<tr>
<td>Vomiting†</td>
<td>1 (2.3%)</td>
<td>3 (7.1%)</td>
</tr>
</tbody>
</table>

* The study protocol specified that adverse events that began within 72 hours of blinded study medication administration were to be classified as at least possibly related to study medication (ie, adverse reactions).
† The following abdominal symptoms were identified in the protocol as associated with HAE abdominal attacks: abdominal pain, bloating, cramps, nausea, vomiting, and diarrhea.

**Table 2: Adverse Reactions Occurring in More Than 4% of Subjects up to 72 Hours After Infusion of Initial or Rescue Medication by Intent-to-Treat, Irrespective of Causality**

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>Number (%) of Subjects Reporting Adverse Reactions</th>
<th>Number (%) of Subjects Reporting Adverse Reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>3 (7%)</td>
<td>11 (26.2%)</td>
</tr>
<tr>
<td>Headache</td>
<td>3 (7%)</td>
<td>5 (11.9%)</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>3 (7%)</td>
<td>5 (11.9%)</td>
</tr>
<tr>
<td>Diarrhea†</td>
<td>4 (9.5%)</td>
<td>9 (20.9%)</td>
</tr>
<tr>
<td>Vomiting†</td>
<td>1 (2.3%)</td>
<td>7 (16.7%)</td>
</tr>
<tr>
<td>Pain†</td>
<td>4 (9.5%)</td>
<td>9 (20.9%)</td>
</tr>
<tr>
<td>Muscle spasms</td>
<td>4 (9.5%)</td>
<td>9 (20.9%)</td>
</tr>
<tr>
<td>Diarrhea†</td>
<td>6 (14%)</td>
<td>12 (28.6%)</td>
</tr>
<tr>
<td>Headache</td>
<td>3 (7%)</td>
<td>6 (14%)</td>
</tr>
<tr>
<td>Vomiting†</td>
<td>1 (2.3%)</td>
<td>2 (4.8%)</td>
</tr>
<tr>
<td>Pain†</td>
<td>2 (4.8%)</td>
<td>4 (9.5%)</td>
</tr>
<tr>
<td>Diarrhea†</td>
<td>4 (9.5%)</td>
<td>8 (18.6%)</td>
</tr>
<tr>
<td>Headache</td>
<td>6 (14%)</td>
<td>12 (28.6%)</td>
</tr>
<tr>
<td>Vomiting†</td>
<td>8 (18.6%)</td>
<td>16 (38.1%)</td>
</tr>
</tbody>
</table>

* The study protocol specified that adverse events that began within 72 hours of blinded study medication administration were to be classified as at least possibly related to study medication (ie, adverse reactions).
† If a subject experienced no relief or insufficient relief of symptoms within 4 hours after infusion, investigators had the option to administer a blinded second infusion (“rescue” treatment) of Berinert 20 units/kg for the placebo group or 10 units/kg for the 40 units/kg group, or placebo (for the 20 units/kg group).
‡ Adverse reactions following either initial treatment and/or blinded “rescue” treatment. Because more subjects in the placebo randomization group than in the Berinert randomization group received rescue treatment, the median observation period in this analysis for subjects randomized to placebo was slightly longer than for subjects randomized to receive Berinert.

Table 3 lists the adverse events that occurred in more than 4% of the subjects 7 to 9 days after the end of a Berinert infusion, irrespective of causality.

**Table 3: Adverse Events Occurring in More Than 4% of Subjects Receiving Berinert at Either 10 Units/kg or 20 units/kg 7 to 9 Days after Infusion, Irrespective of Causality**

<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>Number (%) of Subjects Reporting Adverse Events (n=108)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hereditary angioedema</td>
<td>12 (11.1%)</td>
</tr>
<tr>
<td>Headache</td>
<td>12 (11.1%)</td>
</tr>
<tr>
<td>Abdominal pain†</td>
<td>7 (6.5%)</td>
</tr>
<tr>
<td>Nausea†</td>
<td>7 (6.5%)</td>
</tr>
<tr>
<td>Muscle spasms</td>
<td>6 (5.6%)</td>
</tr>
<tr>
<td>Pain†</td>
<td>6 (5.6%)</td>
</tr>
<tr>
<td>Diarrhea†</td>
<td>5 (4.6%)</td>
</tr>
<tr>
<td>Vomiting†</td>
<td>5 (4.6%)</td>
</tr>
</tbody>
</table>

* Includes subjects in the placebo group who received Berinert 20 units/kg as rescue study medication.
† These symptoms were identified in the protocol as related to the underlying disease. Any increase in intensity or new occurrence of these symptoms after study medication administration was considered to be an adverse event.
‡ Subjects were tested at baseline and after 3 months for possible exposure to Parvovirus B19, hepatitis B, hepatitis C, and HIV-1 and HIV-2. No subject who underwent testing evidenced seroconversion or treatment-emergent positive polymerase chain reaction testing for these pathogens.

**Extension Study**

In an interim safety analysis, of the ongoing open-label extension study, 56 subjects with 559 acute moderate to severe abdominal, facial, and/or laryngeal attacks received a 20 unit/kg body weight dose of Berinert (see Clinical Studies (14)). This study
provides additional safety data in subjects who received multiple infusions of the product for sequential HAE attacks (one infusion per attack).

Table 4 lists the adverse events that occurred in this interim safety analysis of the ongoing open-label extension study in more than 4% of subjects up to 72 hours or 9 days after the end of a Berinert infusion, irrespective of causality.

Table 4: Incidence of Adverse Events by Descending Frequency Occurring in More Than 4% of Subjects Receiving Berinert up to 72 Hours or 9 Days After Infusion, Irrespective of Causality

<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>Number (%) of Subjects Reporting Adverse Events up to 72 hours (n=56)</th>
<th>Number (%) of Subjects Reporting Adverse Events up to 9 Days (n=56)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>3 (5.4%)</td>
<td>4 (7.1%)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>3 (5.4%)</td>
<td>3 (5.4%)</td>
</tr>
<tr>
<td>Hereditary angioedema</td>
<td>2 (3.6%)</td>
<td>4 (7.1%)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>2 (3.6%)</td>
<td>3 (5.4%)</td>
</tr>
</tbody>
</table>

6.2 Postmarketing Experience

Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. Adverse reactions reported in Europe since 1979 in patients receiving Berinert for treatment of HAE include hypersensitivity/anaphylactic reactions, a few suspected cases of viral transmission, including cases of acute hepatitis C, injection-site pain, injection-site redness, chills, and fever.

The following adverse reactions, identified by system organ class, have been attributed to Berinert during post-approval use outside the US:

- Immune System Disorder: Hypersensitivity/anaphylactic reactions, and shock
- General Body: Pain on injection, redness at injection site, chills, and fever

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C. Animal reproduction studies have not been conducted with Berinert. It is not known whether Berinert can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Berinert should be given to a pregnant woman only if clearly needed. In a retrospective case collection study, 20 pregnant women ranging in age from 20 to 35 years received Berinert with repeated doses up to 3,500 units per attack; these women reported no complications during delivery and no harmful effects on their 34 neonates.

8.2 Labor and Delivery

The safety and effectiveness of Berinert administration prior to or during labor and delivery have not been established. Use only if clearly needed.

8.3 Nursing Mothers

It is not known whether Berinert is excreted in human milk. Because many drugs are excreted in human milk, use only if clearly needed when treating a nursing woman.

8.4 Pediatric Use

Safety and efficacy of Berinert in children (ages 0 through 12) have not been established. The clinical studies included an insufficient number of subjects in this age group to determine whether they respond differently from older subjects. The safety and efficacy of Berinert were evaluated in 5 children (ages 3 through 12) and in 8 adolescent subjects (ages 13 through 16) (see Pharmacokinetics [12.3]).

8.5 Geriatric Use

Safety and efficacy of Berinert in the geriatric population have not been established. Clinical studies with Berinert included four subjects older than 65 years. The clinical studies included an insufficient number of subjects in this age group to determine whether they respond differently from younger subjects.

15 REFERENCES


Manufactured by:
CSL Behring GmbH
35041 Marburg, Germany
US License No. 1765

Distributed by:
CSL Behring LLC
Kankakee, IL 60901 USA
Switch to Privigen.

Privigen delivers IVIg therapy that is:

**Simple.**
- Ready-to-use 10% liquid IVIg
- Room temperature storage up to 24 months

**Sophisticated.**
- First and only IVIg stabilized with proline
- Sucrose-free
- IgA ≤ 25 mcg/mL

**Safe.**
- In clinical trials, 97% of related adverse events were non-serious; 95% of 1038 infusions were administered without premedication
- 3-step virus inactivation/removal process, including nanofiltration to 20 nanometers, minimizes the risk of pathogen transmission

For more information about Privigen, visit [www.Privigen.com](http://www.Privigen.com).

---

**Important Safety Information**

Privigen is indicated for the treatment of patients with primary immunodeficiency (PI) associated with defects in humoral immunity, including but not limited to common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

**WARNING:** Renal dysfunction, acute renal failure, osmotic nephrosis, and death may be associated with the administration of Immune Globulin Intravenous (Human) (IVIg) products in predisposed patients. Administer IVIg products at the minimum infusion rate possible. Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIg products containing sucrose. Privigen does not contain sucrose. See full Prescribing Information for complete Boxed Warning. In patients at risk for developing renal failure, monitor urine output and renal function, including blood urea nitrogen and serum creatinine. Thrombotic events have been reported with Privigen and other IVIg treatments. Monitor patients with risk factors for thrombotic events, including a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, hypercoagulable disorders, prolonged periods of immobilization, and/or known or suspected hyperviscosity.

Aseptic meningitis syndrome (AMS) has been reported infrequently with Privigen and other IVIg treatments; AMS may occur more frequently with high doses and/or rapid infusion of IVIg. Hemolysis, hemolytic anemia, and pulmonary adverse events have also been reported. There have been reports of noncardiogenic pulmonary edema in patients administered IVIg. If transfusion-related acute lung injury is suspected, test product and patient for antineutrophil antibodies.

Privigen is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated. In clinical studies, the most common adverse reactions with Privigen were headache, pain, nausea, pyrexia/hyperthermia, fatigue, and chills.

Please see brief summary of full Prescribing Information on following pages.

Privigen is manufactured by CSL Behring AG and distributed by CSL Behring LLC. Privigen is a registered trademark of CSL Behring AG.
CSL Behring

BRIEF SUMMARY OF PRESCRIBING INFORMATION

Privigen®, Immune Globulin Intravenous (Human), 10% Liquid

Before prescribing, please consult full prescribing information, a brief summary of which follows. Some text and references refer to full prescribing information.

WARNING: ACUTE RENAL DYSFUNCTION/FAILURE

Use of Immune Globulin Intravenous (IGIV) products, particularly those containing sucrose, have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephropathy, and death. Patients at risk of acute renal failure include those with any degree of pre-existing renal insufficiency, diabetes mellitus, advanced age (above 65 years of age), volume depletion, sepsis, paraproteinemia, or receiving known nephrotoxic drugs (see Warnings and Precautions [5.2]). Privigen does not contain sucrose. For patients at risk of renal dysfunction or failure, administer Privigen at the minimum infusion rate practicable (see Dosage and Administration [2.3], Warnings and Precautions [5.2]).

1 INDICATIONS AND USAGE

Privigen is an Immune Globulin Intravenous (Human), 10% Liquid indicated for the treatment of patients with chronic immune thrombocytopenic purpura (ITP) to raise platelet counts.

3 DOSAGE FORMS AND STRENGTHS

Privigen is a liquid solution containing 10% IgG (0.1 g/ml) for intravenous infusion.

4 CONTRAINDICATIONS

Privigen is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. Because it contains the stabilizer L-proline, Privigen is contraindicated in patients with hyperprolinemia. Privigen is contraindicated in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity.

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity

Severe hypersensitivity reactions may occur (see Contraindications [4]). In case of hypersensitivity, discontinue the Privigen infusion immediately and institute appropriate treatment. Medications such as epinephrine should be available for immediate treatment of acute hypersensitivity reactions. Privigen contains trace amounts of IgG (≤25 mg/ml) (see Description [1.1]). Patients with known antibodies to IgG may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. Privigen is contraindicated in patients with antibodies against IgG and a history of hypersensitivity reaction (see Contraindications [4.4]).

5.2 Renal Failure

Ensure that patients are not volume depleted before administering Privigen. Periodic monitoring of renal function and urine output is critically important in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of Privigen. Intensity thereafter should be based on renal function deterioration, consider discontinuing Privigen. For patients judged to be at risk of developing renal dysfunction, administer Privigen at the minimum infusion rate practicable (see Boxed Warning, Dosage and Administration [2.3], 2.4).

5.3 Hyperproteinemia

Hyperproteinemia, increased serum viscosity, and hypernatremia may occur in patients receiving Privigen and other IGIV product treatments. It is critical to clinically distinguish true hypernatremia from a pseudohypernatremia that is associated with or causally related to hyperproteinemia with concomitant decreased calculated serum osmolality or elevated osmolar gap, because treatment aimed at decreasing serum free water in patients with pseudohypernatremia may lead to volume depletion, a further increase in serum viscosity, and a possible predisposition to thrombotic events.

5.4 Thrombotic Events

Thrombotic events may occur following treatment with Privigen and other IGIV products. Patients at risk include those with a history of atherothrombosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, coagulation disorders, prolonged periods of immobilization, and/or known suspected hypercoagulability. Consider baseline measurement of blood viscosity in patients at risk for hypercoagulability, including those with cryoglobulins, fasting hyperhomocysteinemia (markedly high triglycerides [triglycerides]), or monoclonal gammopathies. For patients judged to be at risk of developing thrombotic events, begin monitoring at the minimum rate of infusion practicable (see Dosage and Administration [2.3]). Weigh the potential risks and benefits of IGIV against those of alternative therapies in all patients for whom Privigen therapy is being considered.

5.5 Malignancy

Malignancy may occur infrequently with Privigen (see Adverse Reactions [6, 6.1] and other IGIV product treatments. Discontinuation of IGIV treatment has resulted in remission of MDS within several days without sequelae. AML usually begins within several hours to 2 days following IGIV treatment. AML is characterized by the following signs and symptoms: severe headache, nuchal rigidity, drowsiness, fever, pharyngitis, acute myelocytic leukemia, and vomiting (see Patient Counseling Information [17]). Ceftazidime F.J.S. (CSF) studies are frequently positive with leukocyte counts up to several thousand cells per cubic millimeter in patients presenting with granulocytic series, and with elevated protein levels up to several hundred mg/dL. Conduct a thorough neurological examination on patients exhibiting such signs and symptoms, including CSF studies, to rule out other causes of meningitis. AML may occur more frequently in association with high doses (2 g/kg) and/or rapid infusion of IGIV.

5.6 Hemolysis

Privigen may contain blood group antibodies that can act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin reaction and, rarely, hemolysis. Hemolytic anemia can develop subsequent to Privigen therapy due to enhanced RBC sequestration and/or intravascular RBC destruction. Before or possibly intravascular, occur in two subjects treated with Privigen in the ITP study (see Adverse Reactions [6.6, 6.7]). These cases resolved uneventfully. Six other subjects experienced hemolysis in the ITP study as documented from clinical laboratory data. Monitor patients adverse reaction signs of hemolysis (see Patient Counseling Information [17]). If these are present after Privigen infusion, perform appropriate conformational laboratory testing. If transfusion is indicated for patients who develop hemolysis with clinically compromising symptoms after receiving IGIV, perform adequate cross-matching to avoid exacerbating on-going hemolysis.

5.7 Transfusion-Related Acute Lung Injury (TRALI)

Noncardiogenic pulmonary edema may occur in patients following IGIV treatment. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Symptoms typically appear within 1 to 6 hours following treatment. Monitor patients for pulmonary adverse reactions (see Patient Counseling Information [17]). If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and the patient’s serum. TRALI may be managed using oxygen therapy with adequate ventilatory support.

5.8 Volume Overload

The high-dose regimen (1.0 g/kg [for 2 days]) used to treat patients with chronic ITP is not recommended for individuals with expanded fluid volumes or where fluid volume may be of concern (see Dosage and Administration [2.2, 2.3]).

5.9 Transmissible Infectious Agents

Privigen is made from human plasma. Based on effective donor screening and product manufacturing processes (see Description [1.1]), Privigen carries an extremely remote risk of transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered to be extremely remote. No cases of transmission of viral diseases or CJD have been associated with the use of Privigen. All infections suspected by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare professional to CSL Behring Pharmaceuticals at 1-866-913-4541. Before prescribing Privigen, the physician should discuss the risks and benefits of its use with the patient (see Patient Counseling Information [17]).

5.10 Monitoring: Laboratory Tests

Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of Privigen. Intensity thereafter should be based on renal function deterioration, consider discontinuing Privigen. For patients judged to be at risk of developing renal dysfunction, administer Privigen at the minimum infusion rate practicable (see Boxed Warning, Dosage and Administration [2.3], 2.4).

5.11 Interference With Laboratory Tests

After infusion of IgG, the tryptase level of the various passively transferred antibodies in the patient’s blood may yield positive serological tests, resulting in the potential for misleading interpretation. Passive transmission of antibodies to erythrocytes antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coomb’s test) reaction.

6 ADVERSE REACTIONS

The most serious adverse reaction observed in clinical study subjects receiving Privigen for PI was hypersensitivity in one subject. The most common adverse reactions observed in >10% of clinical study subjects with Privigen were headache, pain, nausea, fatigue, and chills. The most serious adverse reactions observed in clinical study subjects receiving Privigen for chronic ITP were asthenic meningitis syndrome in one subject and hemolysis in two subjects. Six other subjects in the ITP study experienced hemolysis as documented from clinical laboratory data (see Warnings and Precautions [5.5, 5.6]). The most common adverse reactions observed in >10% of clinical study subjects with chronic ITP were headache, pyrexia, hypotension, and anemia.

6.1 Clinical Trials Experience

Because different clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials cannot be directly compared to rates in other clinical studies and may not reflect the rates observed in practice. Treatment of Primary Humoral ImmunoDeficiency

In a prospective, open label, single arm, multinational clinical study, 80 subjects with HIV (all of whom had a diagnosis of KIA or HIV) received Privigen intravenously every 3 or 4 weeks for up to 12 months (see Clinical Studies [74]). All subjects had been on regular IGIV replacement therapy for at least 6 months prior to participating in the study. Subjects ranged in age from 3 to 68; 53.5% were male and 42.5% were female. The safety analysis included all 80 subjects in the 3 to 68-week schedule and 64 on the 4-week schedule. The median doses of Privigen administered intravenously ranged from 200 to 888 mg/kg every 3 weeks (median dose 428.3 mg/kg) or 4 weeks (median dose 440.6 mg/kg). A
Table 2: Adverse Events Occurring in >5% of Subjects With PI During a Privigen Infusion or Within 72 Hours After the End of an Infusion, Irrespective of Causality

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Subjects (%)</th>
<th>Infusions (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>35 (41.8)</td>
<td>82 (7.9)</td>
</tr>
<tr>
<td>Pain</td>
<td>20 (25.0)</td>
<td>44 (4.2)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>13 (16.3)</td>
<td>27 (2.6)</td>
</tr>
<tr>
<td>Nausea</td>
<td>10 (12.5)</td>
<td>19 (1.8)</td>
</tr>
<tr>
<td>Chills</td>
<td>9 (11.3)</td>
<td>15 (1.4)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>7 (8.8)</td>
<td>13 (1.3)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>6 (7.3)</td>
<td>10 (1.0)</td>
</tr>
<tr>
<td>Cough</td>
<td>5 (6.3)</td>
<td>5 (0.5)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5 (6.3)</td>
<td>5 (0.5)</td>
</tr>
<tr>
<td>Stomach discomfort</td>
<td>5 (6.3)</td>
<td>5 (0.5)</td>
</tr>
</tbody>
</table>

Table 3: Adverse Events Occurring in >5% Subjects With Chronic ITP During a Privigen Infusion or Within 72 Hours After the End of a Treatment Cycle, Irrespective of Causality

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Subjects (%)</th>
<th>Infusions (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>37 (64.9)</td>
<td>41 (36.0)</td>
</tr>
<tr>
<td>Pyrexia/hyperthermia</td>
<td>21 (36.8)</td>
<td>22 (19.3)</td>
</tr>
<tr>
<td>Nausea</td>
<td>6 (10.5)</td>
<td>6 (5.3)</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>6 (10.5)</td>
<td>6 (5.3)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>6 (10.5)</td>
<td>6 (5.3)</td>
</tr>
<tr>
<td>Blood unconjugated bilirubin</td>
<td>increased</td>
<td>6 (10.5)</td>
</tr>
<tr>
<td>Blood conjugated bilirubin</td>
<td>increased</td>
<td>5 (4.4)</td>
</tr>
<tr>
<td>Blood total bilirubin</td>
<td>increased</td>
<td>4 (3.5)</td>
</tr>
<tr>
<td>Heart rate increased</td>
<td>decreased</td>
<td>3 (2.6)</td>
</tr>
</tbody>
</table>

Two common daily infusions.

Of the 183 temporally associated AE's reported for the 57 subjects with chronic ITP, the investigators judged 150 to be related to the infusion of Privigen (including the one serious AE described below). Of the 149 non-serious AE's related to the infusion of Privigen, 103 were mild, 37 were moderate, 9 were severe. The most common temporally associated AE's judged by the investigators to be "at least probably related to infusions" were headache (65% of subjects) and pyrexia/hyperthermia (55% of subjects).

Three subjects experienced three serious AEs, one of which (asplenia meningitis) was related to the infusion of Privigen.

One patient withdrew from the study due to gingival bleeding, which was not related to Privigen.

Eight subjects, all of whom had a positive DAT, experienced transient drug-related hemolytic reactions, which were associated with elevated bilirubin, elevated lactate dehydrogenase, and a decrease in hemoglobin level within two days after the infusion of Privigen. Two of the eight subjects were clinically anemic but did not require clinical intervention.

Four other subjects with active bleeding were reported to have developed anemia without evidence of hemolysis.

In this study, there was a decrease in hemoglobin after the first Privigen infusion (median decrease of 1.2 g/dL, by Day 8) followed by a return to near baseline by Day 29. Fifty-six of the 57 subjects in this study had a negative DAT at baseline. Of these 56 subjects, 12 (21.4%) developed a positive DAT during the 29-day study period.

6.2 Postmarketing Experience

Because postmarketing reporting of adverse events is voluntary and from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure. Evaluation and interpretation of these postmarketing experiences is confounded by underlying diagnosis, concomitant medications, pre-existing conditions, and inherent limitations of passive surveillance.

Privigen Postmarketing Experience

Adverse reactions reported during worldwide postmarketing use of Privigen do not differ from those which have been observed in clinical studies with Privigen and from what is known for IGIV products.

General

The following mild to moderate reactions may occur with the administration of IGIV products: headache, diarrhea, tachycardia, fever, fatigue, dizziness, malaiae, chills, flushing, skin reactions, wheezing or chest tightness, nausea, vomiting, rigor, back pain, chest pain, myalgia, arthralgia, and changes in blood pressure. Immediate hypersensitivity and anaphylactic reactions are also a possibility. The following adverse reactions have been identified and reported during the post-approval use of IGIV products::1

Renal: Acute renal dysfunction/failure, osmotic nephropathy
Respiratory: Apexia, Acute Respiratory Distress Syndrome (ARDS), TRALI, cyanosis, hypoxemia, pulmonary edema, dyspnea, bronchospasm
Cardiovascular: Cardiac arrest, thromboembolism, vascular collapse, hypotension
Neurological: Coma, loss of consciousness, seizures, tremor, asplenic meningitis synrome
Integumentary: Stevens-Johnson syndrome, epidermolysis, exanthema multiforme, bullous dermatitis
Hematologic: Pancytopenia, leukopenia, hemolysis, positive direct antiglobulin (Coombs) test
Musculoskeletal: Back pain
Gastrointestinal: Hepatic dysfunction, abdominal pain
General/Body as a Whole: Pruritus, rigors

7 DRUG INTERACTIONS

Passive transfer of antibodies may transiently interfere with the immune response to live virus vaccines such as measles, mumps, and rubella.1 The immunizing physician should be informed of recent therapy with Privigen so that appropriate measures may be taken (see Patient Counseling Information 17).

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C. Animal reproduction studies have not been conducted with Privigen. It is not known whether Privigen can cause fetal harm when administered to a pregnant woman or can affect reproductive capability. Privigen should be given to pregnant women only if clearly needed, immunoglobulins cross the placenta from maternal circulation increasing after 20 weeks of gestation.1,13,15

8.2 Nursing Mothers

Use of Privigen in nursing mothers has not been evaluated.

8.4 Pediatric Use

Treatment of Primary Humoral Immunoodeficiency

Privigen was evaluated in 31 pediatric subjects (19 children and 12 adolescents) with PI. There were no apparent differences in the safety and efficacy profiles as compared to those in adult subjects. No pediatric-specific dose requirements were necessary to achieve the desired serum IgG levels. The safety and effectiveness of Privigen have not been established in pediatric patients with PI who are under the age of 3.

Treatment of Chronic Immune Thrombocytopenia Purpura

Safety and effectiveness of Privigen have not been established in pediatric patients with chronic ITP who are under the age of 15.

US License No. 1766

Distributed by:
CSSL Behring LLC
Kankakee, IL 60901 USA
Based on June 2009 revision.
When prescribing SCIg therapy...

Make the leap to Hizentra—
a 20% SCIg

Introducing Hizentra—
The first and only FDA-approved 20% SCIg* therapy

- Room temperature storage
- Manufactured by CSL Behring, maker of the first FDA-approved SCIg

For more information, visit www.Hizentra.com.

Important Safety Information

Immune Globulin Subcutaneous (Human), Hizentra, is indicated as replacement therapy for patients with primary humoral immunodeficiency (PI). This includes but is not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin preparations or components of Hizentra, such as polysorbate 80. Because it contains the stabilizer L-proline, Hizentra is contraindicated in patients with hyperprolinemia. Hizentra is also contraindicated in patients with immunoglobulin A deficiency who have known antibody against IgA and a history of hypersensitivity.

All IgA-deficient patients with anti-IgA antibodies are at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. If hypersensitivity occurs or anaphylactic reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Hizentra is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most common drug-related adverse reactions (observed in 5% or more of subjects in the clinical trial) were local reactions (ie, swelling, redness, heat, pain, and itching at the injection site), headache, vomiting, pain, and fatigue.

Monitor patients for reactions reported to occur with IVIg treatment that might also occur with Hizentra, including renal dysfunction/failure, thrombotic events, aseptic meningitis syndrome (AMS), hemolysis, and transfusion-related acute lung injury (TRALI).

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella. It can also lead to misinterpretation of serologic testing.

No overall differences in safety or efficacy were observed in patients over 65 or in pediatric patients. In the clinical study, desired serum IgG levels were achieved in pediatric patients without pediatric-specific dose requirements.

Please see brief summary of full Prescribing Information on next page.
Hizentra is contraindicated in IgA-deficient patients with antibodies against IgA and a history of aseptic meningitis syndrome (AMS). The syndrome usually begins within several hours to 2 days following IVIG treatment. AMS may occur more frequently in association with high doses (2 g/kg) and/or rapid infusion of IGIV. By US Food and Drug Administration (FDA) criteria, the clinical profile of AMS is characterized by signs and symptoms including severe headache, nuchal rigidity, drowsiness, fever, hypotension, photophobia, painful eye movements, nausea, and vomiting. Cerebrospinal fluid (CSF) studies frequently show pleocytosis up to several thousand cells per cubic millimeter, predominantly from the granulocytic series, with elevated protein levels up to several hundred mg/dL. AMS may occur more frequently in association with high doses (2 g/kg) of IGIV. Hizentra contains L-proline (see Description [11]).

5.2 Reactions Reported to Occur With IGIV Treatment

The following reactions have been reported to occur with IGIV treatment and may occur with Hizentra treatment: renal dysfunction/failure, cosinophilic nephropathy, and death may occur with use of human immune globulin products. Ensure that patients are not volume depleted and assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of Hizentra and at appropriate intervals thereafter. Periodic monitoring of renal function and urine output is particularly important in patients judged to have a potential increased risk of developing acute renal failure. If renal function deteriorates, consider discontinuing Hizentra. For patients judged to be at risk of developing renal dysfunction because of pre-existing renal insufficiency or predisposition to acute renal failure (such as those with diabetes mellitus or hypoproteinemia), who are overweight or use concomitant nephrotic medicinal products, or those who are over 65 years of age, administer Hizentra at the minimum rate practicable.

5.3 Transmissible Infectious Agents

Because Hizentra is made from human plasma, it may carry a risk of transmitting infectious agents (e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease [CJD] agent). The risk of infectious agent transmission has been reduced by screening plasma donors for prior exposure to certain viruses, testing for the presence of certain current virus infections, and including virus inactivation/removal steps in the manufacturing process for Hizentra.

Results of tests for agents that can be transmitted by blood components containing IgA.

<table>
<thead>
<tr>
<th>Agents</th>
<th>Number of Subjects</th>
<th>Number (Rate) of Subjects</th>
<th>Number (Rate) of Infusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td>205</td>
<td>1 (0.54)</td>
<td>205 (1.00)</td>
</tr>
<tr>
<td>HBV</td>
<td>195</td>
<td>0 (0.00)</td>
<td>195 (1.00)</td>
</tr>
<tr>
<td>HCV</td>
<td>207</td>
<td>0 (0.00)</td>
<td>207 (1.00)</td>
</tr>
</tbody>
</table>

HIV, HBV, and HCV are major blood-borne viruses that can cause serious disease if not controlled. Hizentra can contain blood group antibodies that may act as hemolysins and induce intravascular hemolysis, consistent with intravascular hemolysis, has been reported. 

5.4 Laboratory Tests

Various passively transferred antibodies in immunoglobulin preparations may lead to misinterpretation of the results of serological testing.

ADVERSE REACTIONS

The most common adverse reactions (ARs) observed in ≥5% of subjects receiving Hizentra were local reactions (i.e., swelling, redness, heat, pain, and itching at the injection site). AEs occurring in ≥1% of study subjects receiving Hizentra and ≥1% of control subjects receiving IGIV are included in Table 1.

Table 1: Incidence of Subjects With Adverse Events (AEs) (Experienced by 4 or More Subjects) and Rate per Infusion, Irrespective of Causality (ITT Population)

<table>
<thead>
<tr>
<th>AE (≥4 Subjects)</th>
<th>All AEs*</th>
<th>AEs* Occurring During or Within 72 Hours of Infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number (% of Subjects (n=49))</td>
<td>Number (Rate) of AEs (n=2264 Infusions)</td>
</tr>
<tr>
<td></td>
<td>49 (100)</td>
<td>1340 (0.592)</td>
</tr>
<tr>
<td>Local reactions</td>
<td></td>
<td>49 (100)</td>
</tr>
</tbody>
</table>

AEs occurring in ≥1% of subjects are included in Table 2 (Experienced by 4 or More Subjects) and rate per infusion, irrespective of causality. AEs occurring in ≥1% of study subjects are included in Table 2 (Experienced by 4 or More Subjects) and rate per infusion, irrespective of causality.
Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.

### Table 4: Investigator Assessments of Injection-Site Reactions by Infusion

<table>
<thead>
<tr>
<th>AE (≥8 Subjects)</th>
<th>Number (% of Subjects (n=49))</th>
<th>Number (% of Subjects (n=2264 Infusions))</th>
<th>Number (% of Subjects (n=49))</th>
<th>Number (% of Subjects (n=2264 Infusions))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>12 (26.5)</td>
<td>40 (0.018)</td>
<td>12 (24.5)</td>
<td>52 (0.014)</td>
</tr>
<tr>
<td>Cough</td>
<td>5 (10.2)</td>
<td>3 (0.006)</td>
<td>4 (8.2)</td>
<td>24 (0.005)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5 (10.2)</td>
<td>4 (8.2)</td>
<td>5 (10.2)</td>
<td>6 (0.003)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4 (8.2)</td>
<td>3 (0.006)</td>
<td>4 (8.2)</td>
<td>24 (0.005)</td>
</tr>
<tr>
<td>Nausea</td>
<td>5 (10.2)</td>
<td>4 (8.2)</td>
<td>5 (10.2)</td>
<td>6 (0.003)</td>
</tr>
<tr>
<td>Abdominal pain, upper</td>
<td>5 (10.2)</td>
<td>4 (8.2)</td>
<td>5 (10.2)</td>
<td>6 (0.003)</td>
</tr>
<tr>
<td>Rash</td>
<td>5 (10.2)</td>
<td>4 (8.2)</td>
<td>5 (10.2)</td>
<td>6 (0.003)</td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>4 (8.2)</td>
<td>3 (0.006)</td>
<td>4 (8.2)</td>
<td>24 (0.005)</td>
</tr>
<tr>
<td>Migraine</td>
<td>4 (8.2)</td>
<td>3 (0.006)</td>
<td>4 (8.2)</td>
<td>24 (0.005)</td>
</tr>
<tr>
<td>Pain</td>
<td>4 (8.2)</td>
<td>3 (0.006)</td>
<td>4 (8.2)</td>
<td>24 (0.005)</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>4 (8.2)</td>
<td>2 (0.004)</td>
<td>4 (8.2)</td>
<td>2 (0.004)</td>
</tr>
<tr>
<td>Pharyngolaryngeal pain</td>
<td>4 (8.2)</td>
<td>2 (0.004)</td>
<td>4 (8.2)</td>
<td>2 (0.004)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>4 (8.2)</td>
<td>2 (0.004)</td>
<td>4 (8.2)</td>
<td>2 (0.004)</td>
</tr>
</tbody>
</table>

### Table 2: (Continued)

The following adverse reactions have been identified and reported during the postmarketing use of IG products:
- **Infusion reactions:** Hypersensitivity (e.g., anaphylaxis), headache, diaphoresis, fever, fatigue, dizziness, malaise, chills, flushing, urticaria or other skin reactions, wheezing or other chest discomfort, nausea, vomiting, rigors, back pain, myalgia, arthralgia, and changes in blood pressure.
- **Renal:** Acute renal dysfunction/failure, osmotic nephropathy.
- **Respiratory:** Anergy, Acute Respiratory Distress Syndrome (ARDS), TRALI, cyanosis, hypoxemia, pulmonary edema, dyspnea, bronchospasm.
- **Cardiovascular:** Cardiac arrest, thromboembolism, vascular collapse, hypotension.
- **Neurological:** Coma, loss of consciousness, seizures, tremor, aseptic meningitis syndrome.
- **Integumentary:** Stevens-Johnson syndrome, epidermolysis, exfoliative dermatitis, bullous dermatitis.
- **Hematologic:** Pancreatitis, leukopenia, hemolysis, positive direct antiglobulin (Coombs') test.
- **Gastrointestinal:** Hepatic dysfunction, abdominal pain.
- **General/Body as a Whole:** Pyrexia, rigors.

Report to SUSPECTED ADVERSE REACTIONS, contact CSL Behring Pharmacovigilance at 1-866-915-8958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

#### 7 DRUG INTERACTIONS

#### 7.1 Live Virus Vaccines

The passive transfer of antibodies with immunoglobulin administration may interfere with the response to live virus vaccines such as measles, mumps, rubella, and varicella (see **Patient Counseling Information**).

#### 7.2 Serological Testing

Various passively transferred antibodies in immunoglobulin preparations may lead to misinterpretation of the results of serological testing.

#### 8 USE IN SPECIFIC POPULATIONS

#### 8.1 Pregnancy

Pregnancy Category C. Animal reproduction studies have not been conducted with Hizentra. It is not known whether Hizentra can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Hizentra should be given to pregnant women only if clearly needed.

#### 8.3 Nursing Mothers

Hizentra has not been evaluated in nursing mothers.

#### 8.4 Pediatric Use

Hizentra was evaluated in 10 pediatric subjects (3 children and 7 adolescents) with PI. No pediatric-specific dose requirements were necessary to achieve the desired serum IgG levels.

Hizentra was not evaluated in neonates or infants.

#### 8.5 Geriatric Use

Of the 49 subjects evaluated in the clinical study of Hizentra, 6 subjects were 65 years of age or older. No overall differences in safety or efficacy were observed between these subjects and younger subjects.

#### 15 REFERENCES


Manufactured by:

Distributed by:

CSL Behring AG
Kankakee, IL 60901 USA
CSL Behring LLC
Kankakee, IL 60901 USA
US License No. 1765

Based on March 2010 version.
BD Biosciences flow cytometry systems

In a perpetual state of the art.

At BD Biosciences, we’re always thinking about what’s next in flow cytometry and multicolor analysis. Since commercializing the first cell sorter in 1973, we’ve been delivering flow cytometry systems that are more powerful, more dependable, and easier to use.

We innovate to keep you in a perpetual state of the art, because when we do, your work goes more smoothly, clearing the way to faster discovery and better clinical care.

From special order systems that support advanced research to clinical solutions that streamline care, you can depend on BD systems to make your job easier, your workflow more efficient, and your results more reliable, today and tomorrow.

Innovation is built in. You can depend on it.

bdbiosciences.com/innovation

Class I (1) Laser Product
BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2010 BD
23-11480-01
Introducing the BD LSRFortessa

The ultimate tool for choice, power, and consistency in flow cytometry, the BD LSRFortessa™ cell analyzer is an affordable solution, innovatively designed to meet your ever-advancing needs. Available with up to 4 lasers including blue, red, violet, and ultraviolet, the instrument can accommodate the detection of up to 18 colors simultaneously, ready to meet assay requirements today and tomorrow.

Of course, the BD LSRFortessa comes with innovation built in. Using patented technologies such as the gel-coupled cuvette and octagon and trigon detection systems, you get unrivaled sensitivity and resolution in a benchtop-sized device. And if you need a custom configuration to meet advanced requirements, the BD special order program offers an unparalleled range of color, wavelength, and power choices.

Find out how you can keep your lab in a perpetual state of the art at bdbiosciences.com/fortessa.

Innovation is built in. You can depend on it.

bdbiosciences.com/fortessa

Class I (1) Laser Product.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2010 BD
23-11695-00

BD Biosciences
2350 Qume Drive
San José, CA 95131
bdbiosciences.com
PerkinElmer puts faster, easier inflammation assays within reach.

AlphaLISA® is a homogeneous alternative to conventional ELISA, enabling you to eliminate tedious wash steps without sacrificing high sensitivity or wide dynamic range. And with our expanding line of AlphaLISA kits for research on cancer, inflammation and other disease areas, we’re bringing this highly efficient Alpha Technology to more labs than ever before. Learn more about our exclusive Alpha Technology assays, and all the ways we can give you a hand with your research.

www.perkinelmer.com/nowashelisainflammation
BD Flow Cytometry Systems

BD patented collection optics are set up in octagon- and trigon-shaped optical pathways to maximize signal detection from each laser-illuminated beam spot. It’s an innovation that allows more colors to be detected with minimum light loss. This unique design also makes it easier for researchers to change filters and mirrors in the optical arrays, and requires no further alignment for maximum signal strength.

Yet another way that BD is making flow cytometry more powerful and easier to use while keeping you in a perpetual state of the art.

Innovation. To be continued.

GRIP
Grant Review for Immunologists Program

Get a GRIP: An AAI program designed to help new investigators prepare their NIH grant proposals

AAI is pleased to offer a program to match new PI’s with established PI’s who have significant, successful grant writing careers. The Grant Review for Immunologists Program (GRIP) invites new PI’s to submit an outline or NIH-style abstract to the GRIP coordinator who, with the assistance of a small volunteer subcommittee, will attempt to match the topic of the proposal with the research experience of an established PI. Matches will be made as quickly as possible to allow new PI’s to meet upcoming NIH grant deadlines. Participation is strictly voluntary and is not intended to supplant internal mentoring programs.

GRIP is now accepting both new PI and established PI participants. Please send your CV and a brief description of either your potential research project (new PI’s) or grant reviewing experience (established PI’s) to infoaai@aai.org (please write “GRIP” in the subject line).

Program details at www.aai.org/GRIP_rd.htm
BD Flow Cytometry Systems

The BD special order program has supported research at the leading edge of biomedical discovery since 2005. The custom configuration of BD flow cytometers and cell sorters provides you with a precise fit for your research and assay needs. BD's continuous and vigorous pursuit of the latest and best laser technologies ensures that the evolving needs of leading research are always met.

BD innovation gives you unparalleled choice of configuration and capabilities to keep you in a perpetual state of the art.

Innovation. To be continued.

Visit us to

- Learn about NIH funding
- Keep current on key policy issues
- Discover how you can help AAI in its advocacy initiatives

Go to www.aai.org and select Public Affairs from the right-hand links.
INTRODUCING OUR NEW

PROTEOMICS RESEARCH PRODUCTS CATALOG

FROM THE LEADING SUPPLIER OF PROTEOMICS RESEARCH PRODUCTS:

- Over 16,450 monoclonal and 32,930 polyclonal antibodies
- Over 135,300 siRNA and shRNA (plasmid and lentivirus) products
- UltraCruz®, ExactaCruz®, and CrystalCruz® brand labware
- Over 68,000 ChemCruz® specialty biochemicals
- Broad range of support products and secondary antibodies
- Website updated daily with new antibodies, biochemicals, labware, product citations and support data.

© 2010 Santa Cruz Biotechnology, Inc., the Santa Cruz Biotechnology, Inc. logo, UltraCruz™, ExactaCruz™, ChemCruz™, ImmunoCruz™ and CrystalCruz™ are registered trademarks of Santa Cruz Biotechnology, Inc.
Jurkat T cell leukemia cell line were untreated (A), treated with 0.0038 μg/ml (B) or 0.25 μg/ml (C) LEAF™ Purified anti-CD95 (clone EOS9.1) for 4 hrs then stained with Annexin V FITC and 7-AAD.

Get the best results for the best price. Let's make a deal today!